Archive

Strategy, appointments, major clinical, medical and regulatory advances, and partnerships: you can find all the latest Ipsen Group press releases here.

TAZVERIK ® + R2 2L LF
ONIVYDE ® + 5-FU/LV + OXALIPLATIN 1L PDAC
CABOMETYX ® + ATEZOLIZUMAB 2L mCRPC
CABOMETYX ® + ATEZOLIZUMAB 2L NSCLC
TAZVERIK® (+ hormonothérapies) CRPCm
TAZVERIK® (différentes combinaisons) Hémopathies malignes R/R
IPN60210 Myélome multiple R/R et R/R LDGCB
Onivyde® ACP 1L2
Onivyde® CBPC 2L1
Cabometyx + atezolizumab mCPHR 2L2
© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023